MétaCan
Menu
Back to cohort
Record W4405813241 · doi:10.1093/cid/ciae622

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study

2024· article· en· W4405813241 on OpenAlexaff
Terry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, Conrado J. Llapur, Olga Voloshyna, Ezekiel Fink, Ángela Gentile, Garry Wallace, Peter Richmond, Joseph B. Domachowske, Thembile Mzolo, Maria Lattanzi, Daniela Toneatto, Adebayo Akinsola, Madhavi Ampajwala, Mark Arya, Andrew Bartlett, Divya Batra, Mark Bloch, José Bordón, William Byars, Jeremy Peter James Carr, Ana Ceballos, Ferdinandus de Looze, Mercedes Deluca, Rand Farjo, Jennifer Gilsoul, Elizabeth Gunner, Anil Kumar Gupta, Matthew Hong, Julie Kasarjian, Gonzalo Pérez Marc, Paul Matherne, Gretchen Mitchell, Mora Obed, Peter Richmond, Fernando Riera, Walter Rok, Louis Saravolatz, Peter Silas, Adriana Soto, Katherine J. Sullivan, Joseph Surber, Ricardo Teijeiro, Florence Tiong, Ushma Wadia, Clifford Yut

Bibliographic record

VenueClinical Infectious Diseases · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBacterial Infections and Vaccines
Canadian institutionsUniversity of Guelph
FundersModernaNovavaxShionogiSanofiGlaxoSmithKlineSeqirusAstraZenecaPfizer
KeywordsReactogenicityMedicineMeningococcal vaccineImmunogenicityVaccinationMeningococcal diseaseNeisseria meningitidisConfidence intervalTiterRandomized controlled trialPediatricsImmunologyInternal medicineAntigenImmunizationAntibody

Abstract

fetched live from OpenAlex

BACKGROUND: A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases. METHODS: In this phase 3 study, healthy participants aged 15-25 years, who had received MenACWY vaccination ≥4 years previously, were randomized (1:1) to receive 2 MenABCWY doses 6 months apart or 1 MenACWY-CRM dose. Primary objectives were to demonstrate the noninferiority of MenABCWY 1 month postvaccination versus MenACWY-CRM, with a lower limit of 2-sided 95% confidence interval above -10% for group differences in 4-fold rise in human serum bactericidal antibody (hSBA) titers against serogroups ACWY, and to evaluate reactogenicity and safety. Secondary endpoints included percentages of participants with hSBA titers greater than or equal to the lower limit of quantitation (≥LLOQ) against serogroups ACWY and vaccine antigen-specific serogroup B (MenB) indicator strains. RESULTS: Noninferiority of MenABCWY versus MenACWY-CRM was demonstrated following each MenABCWY dose. Percentages of participants with hSBA titers ≥LLOQ for serogroups ACWY were 97.9%-98.9% and 99.5%-100% following 1 and 2 MenABCWY doses, respectively, and 96.8%-99.0% following 1 MenACWY-CRM dose. After 2 MenABCWY doses, 75.6%-96.3% of participants had hSBA titers ≥LLOQ against MenB indicator strains. The MenABCWY vaccine was well tolerated in MenACWY-primed individuals, with a favorable safety profile. CONCLUSIONS: Immune responses against serogroups ACWY following 1 and 2 doses of investigational MenABCWY vaccine are noninferior to those following MenACWY-CRM in MenACWY-primed adolescents and young adults. Robust immune responses were observed against MenB indicator strains after 2 MenABCWY doses administered 6 months apart. Clinical Trials Registration. NCT04707391.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.349
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicBacterial Infections and VaccinesFrench-language works237,207